Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Knowledge-Informed Machine Learning for Cancer Diagnosis and Prognosis: A Review
Mao, Lingchao , Wang, Hairong, Hu, Leland , Tran, Nhan L. , Canoll, Peter , Swanson, Kristin R. , Li, Jing , Wang, Hairong , Hu, Leland S , Mao, Lingchao , Swanson, Kristin R , Tran, Nhan L , Li, Jing

Mayo Clinic

IEEE Transactions on Automation Science and Engineering | December 18, 2024 | Volume: 22 | Issue: No issue available | Pages: 10008-10028

10.1109/tase.2024.3515839 | PMID 40893871 Get It

Targeted therapy‑associated cardiotoxicity in patients with stage‑IV lung cancer with or without cardiac comorbidities
Peng, Yanmei , Li, Dong , Gu, Zhong, Kosuru, Nikhila, Yu, Nathan Y. , Wang, Zhichao , Leventakos, Konstantinos , Ernani, Vinicius , Wampfler, Jason A. , Luo, Yung‐Hung , Kumar, Ashok, Yang, Ping

Mayo Clinic

Oncology Reports | December 18, 2024 | Volume: 53 | Issue: 2 | Pages: No page available

10.3892/or.2024.8858 | PMID 39704259 Get It

Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database
Rachmasari, Kharisa N. , Venker, Brett, Arackal, Joel, Miller‐Wilson, Lesley‐Ann , Schwinn, Jennifer, Mina‐Osorio, Paola , Stan, Marius N. , Wagner, Lilly H. , Wang, Jingyu

Mayo Clinic

Clinical Endocrinology | December 18, 2024 | Volume: 102 | Issue: 4 | Pages: 482-489

10.1111/cen.15183 | PMID 39690929 Get It

ABSTRACT Objective To estimate the incidence, prevalence, patient characteristics and healthcare utilization patterns of moderate to severe thyroid eye disease (TED) in the United States. Design Retrospective review of medical and prescription claims data from the Inovalon deidentified claims database. Patients Patients with moderate to severe TED were identified based on specific and sensitive definitions using International Classification of Diseases (ICD) codes selected by a group of TED specialists. Results The incident moderate to severe TED population included 3364 and 1730 patients using the sensitive and specific definitions, respectively. After adjusting for age and gender, corresponding incidence rates in the sensitive and specific populations were 8.97 (13.49 in women and 4.27 in men) and 4.37 (6.59 in women and 2.05 in men) per 100,000 person‐years, respectively. The prevalent population included 16,310 and 8018 patients using the sensitive and specific definitions, respectively, corresponding to adjusted prevalence rates of 44.13 (66.00 in women and 21.39 in men) and 20.55 (31.18 in women and 9.50 in men) per 100,000 persons. A preponderance of women was observed, and comorbidity rates were high, with > 40% of prevalent patients experiencing hypertension. Steroids were the most frequently prescribed medication. The impact of teprotumumab was not captured, since this study only included claims data through 2019. Conclusions The estimated incidence and prevalence rates of TED demonstrate the considerable impact of this disease in the United States, making the creation of a specific ICD code imperative for effective healthcare planning and management.
Non-pharmaceutical treatments for irritable bowel syndrome
Shapiro, Jordan , Wang, Xiao‐Jing , Thakur, Elyse R.

Mayo Clinic

BMJ | December 18, 2024 | Volume: 387 | Issue: No issue available | Pages: e075777

10.1136/bmj-2023-075777 | PMID 39681399 Get It

Abstract Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction that impacts a significant portion of the population and is associated with substantial morbidity, reduced quality of life, and economic impact globally. The pathophysiology of IBS is complex and incompletely understood, and the heterogeneity of IBS is reflected in the variety of pharmaceutical and non-pharmaceutical therapies utilized for the management of IBS. Given limitations with pharmaceutical treatments, many patients with IBS seek non-pharmaceutical options. Several non-pharmaceutical treatments such as the low FODMAP diet and brain-gut behavior interventions such as gut directed hypnosis and cognitive behavioral therapy are now considered standard of care and are part of all major guidelines for the treatment of IBS. However, challenges with access to and optimal implementation of these therapies remain. This review focuses on the current evidence for common non-pharmaceutical treatments for IBS, including the latest advances in dietary and brain-gut behavioral care, in addition other complementary and integrative health practices and emerging therapies.
A self-attention-driven deep learning framework for inference of transcriptional gene regulatory networks
Zhong, Le, Chen, Zhuobin, Yu, Yanjia , Yu, Dan, Qin, Jing , Wang, Junwen , Yu, Dan , Qin, Jing , Wang, Junwen , Liu, Yong , Yan, Bin, Chen, Zhuobin

Mayo Clinic

Briefings in Bioinformatics | December 16, 2024 | Volume: 26 | Issue: 1 | Pages: No page available

10.1093/bib/bbae639 | PMID 39679439 Get It

Abstract The interactions between transcription factors (TFs) and the target genes could provide a basis for constructing gene regulatory networks (GRNs) for mechanistic understanding of various biological complex processes. From gene expression data, particularly single-cell transcriptomic data containing rich cell-to-cell variations, it is highly desirable to infer TF–gene interactions (TGIs) using deep learning technologies. Numerous models or software including deep learning–based algorithms have been designed to identify transcriptional regulatory relationships between TFs and the downstream genes. However, these methods do not significantly improve predictions of TGIs due to some limitations regarding constructing underlying interactive structures linking regulatory components. In this study, we introduce a deep learning framework, DeepTGI, that encodes gene expression profiles from single-cell and/or bulk transcriptomic data and predicts TGIs with high accuracy. Our approach could fuse the features extracted from Auto-encoder with self-attention mechanism and other networks and could transform multihead attention modules to define representative features. By comparing it with other models or methods, DeepTGI exhibits its superiority to identify more potential TGIs and to reconstruct the GRNs and, therefore, could provide broader perspectives for discovery of more biological meaningful TGIs and for understanding transcriptional gene regulatory mechanisms.
Effect of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction Across the Age Spectrum in PARAGON-HF
Claggett, Brian, Chatur, Safia , O’Meara, Eileen , Rouleau, Jean L. , Redfield, Margaret M. , Lam, Carolyn, Packer, Milton, Shah, Amil M. , Čikeš, Maja , Pfeffer, Marc A., Solomon, Scott D. , Redfield, Margaret, Shah, Amil , Wang, Xiaowen , Vardeny, Orly , Claggett, Brian , Vaduganathan, Muthiah , Hegde, Sheila M. , Skali, Hicham , Pabón, Maria A. , Foà, Alberto , Kosztin, Annamária , Lam, Carolyn S.P. , Zile, Michael R. , Packer, Milton , Gori, Mauro , Merkely, Béla , McMurray, John J.V. , Solomon, Scott David

Mayo Clinic

European Journal of Heart Failure | December 15, 2024 | Volume: 27 | Issue: 1 | Pages: 96-106

10.1002/ejhf.3535 | PMID 39675788 Get It

Abstract Aims To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial. Methods and results A total of 4796 participants ≥50 years of age with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) ≥45% were divided into three age groups: <65 years (n = 825), 65–74 years (n = 1772), and ≥75 years (n = 2199). Echocardiograms of 1097 patients were analysed in a standardized fashion at a core imaging laboratory. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death. Older patients were more likely to experience primary composite outcomes (compared to patients <65 years, adjusted rate ratio [aRR] for ≥75 years: 1.39, 95% confidence interval [CI] 1.21–1.61), total HF hospitalization (aRR 1.27, 95% CI 1.09–1.49), and CV death (adjusted hazard ratio [aHR] 2.04, 95% CI 1.44–2.87). Age did not modify the effect of sacubitril/valsartan compared to valsartan on primary composite endpoint (pinteraction = 0.79) in the overall population or in those with LVEF ≤57%. Older adults randomized to sacubitril/valsartan were more likely to develop hypotension compared to those receiving valsartan (pinteraction = 0.026). Older patients had smaller left ventricular chamber sizes, higher LVEF, and were more likely to have abnormal measures of diastolic function. Conclusion Older patients with HF with preserved ejection fraction had higher event rates than younger patients, more adverse events overall, and more hypotension when treated with sacubitril/valsartan; however, the treatment benefits of sacubitril/valsartan were retained in older patients.
Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast Cancer
Huang, Chen , Srinivasan, Ramakrishnan Rajaram , Lewis, Alaina , Sallas, Christina , Zhao, Na , Cao, Jin , Pilcher, Jacob B., Moon, Chang In, Liao, Yuxing , Rimawi, Mothaffar F. , Malovannaya, Anna , Li, Shunqiang , Kraushaar, Daniel C. , Goetz, Matthew P., Boughey, JC , Wang, Liewei, Kalari, Krishna R., Suman, Vera J., Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, F, Welm, Bryan E. , Welm, Alana L. , Zhang, Bing , Lei, Jonathan T , Zhao, Na , Wen, Bo , Rimawi, Mothaffar , Lei, Jonathan T. , Dobrolecki, Lacey E. , Vasaikar, Suhas , Landua, John David , Pilcher, Jacob B. , Hilsenbeck, Susan Galloway , Ellis, Matthew J. , Petrosyan, Varduhi, Li, Kai shang , Saltzman, Alexander B. , Jain, Antrix , Wulf, Gerburg M. , Marangoni, Elisabetta , Wang, Tao , Goetz, Matthew P. , Damodaran, Senthil , Zheng, Xiaofeng , Meric‐Bernstam, Funda , Echeverria, Gloria Vittone , Anurag, Meenakshi , Chen, Xi , Lewis, Michael T.

Mayo Clinic

No container title available | December 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.12.09.627518 | PMID 39713418 Get It

Abstract Chemotherapy regimens for triple-negative breast cancer (TNBC) combine agents without knowing which agents drive response. Consequently, predictors derived from multi-agent regimens cannot be assumed to generalize to individual drugs or other regimens, motivating development of treatment-matched predictors. Here, we used TNBC patient-derived xenografts (PDXs) treated with carboplatin, docetaxel, or the combination to deconvolute drug-specific responses and identify associated molecular features. Combination treatment rarely improved upon the best single agent, with enhanced responses in only 13% of PDXs and antagonism in a comparable fraction. Proteogenomic analyses identified high cytokeratin-5 (KRT5) as a general marker of chemotherapy responsiveness and KRT5 immunohistochemistry discriminated responsive PDXs (AUROC, 0.83). To train treatment-specific predictors, we integrated these data with independent PDX and clinical cohorts with responses assessed after anthracycline-free platinum, taxane, or platinum-taxane therapy, ensuring response corresponded to the modeled treatment. Four feature selection strategies yielded largely nonoverlapping biomarker panels converging on treatment-relevant pathways. On independent test data, RNA-based predictors of complete response (CR) to platinum-based (carboplatin or cisplatin) and taxane-based (docetaxel or paclitaxel) chemotherapy achieved AUROCs of 0.80 and 0.86, respectively. For platinum-taxane regimens (carboplatin plus docetaxel or paclitaxel), proteomic-guided feature selection generated a 10-biomarker, protein- informed RNA predictor of pathologic complete response (pCR) that outperformed RNA-only feature selection and achieved an AUROC of 0.85 in an independent clinical cohort, while retaining practicality as an RNA-based assay. Treatment-matched integration of multi-omic PDX and clinical datasets provides a framework for chemotherapy-specific predictors with clinically relevant performance, supporting biomarker-guided precision selection and treatment optimization for patients with TNBC. Statement of significance Integration of multi-omic data from patient-derived xenografts with treatment-matched clinical cohorts yielded three retrospectively validated predictors of platinum, taxane, and platinum+taxane response, enabling biomarker-guided chemotherapy selection for patients with triple-negative breast cancer.
Associations Between Maternal Periconceptional Alcohol Consumption and Risk of Craniosynostosis Among Offspring, National Birth Defects Prevention Study, 1997–2011
Fisher, Sarah C. , Romitti, Paul A. , Howley, Meredith M. , Browne, Marilyn L. , Study, the National Birth Defects Prevention, Howley, Meredith M , Jabs, Ethylin Wang, Browne, Marilyn L , Tracy, Melissa , Jabs, Ethylin W , Study, the National Birth Defects Prevention

Mayo Clinic

Birth Defects Research | December 12, 2024 | Volume: 116 | Issue: 12 | Pages: No page available

10.1002/bdr2.2420 | PMID 39665132 Get It

ABSTRACTBackgroundPrevious studies of maternal alcohol consumption and craniosynostosis have reported null or inverse associations. We updated a previous analysis of National Birth Defects Prevention Study (NBDPS) data to further examine associations between maternal alcohol consumption and craniosynostosis.MethodsNBDPS was a multi‐site, population‐based case–control study. Mothers of craniosynostosis cases and randomly selected liveborn controls delivered during 1997–2011 completed a telephone interview about pregnancy exposures. We examined associations for self‐reported periconceptional maternal alcohol consumption (during the month before conception through the third gestational month) and odds of craniosynostosis in offspring. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between any alcohol consumption and binge consumption and craniosynostosis, overall and by affected suture. Finally, we performed a probabilistic bias analysis using a range of assumptions about the sensitivity and specificity of self‐reported consumption by case/control status.ResultsWe analyzed interview data from 1435 mothers of craniosynostosis cases and 11,216 mothers of controls. Periconceptional alcohol consumption prevalence was similar among case (36.9%) and control (38.2%) mothers. We observed point estimates near or below 1.0 for alcohol consumption (any and binge) and all suture subtypes of craniosynostosis, with all CIs including the null. Our bias‐adjusted estimates for periconceptional alcohol consumption were higher than our conventional estimates but supported the null findings.ConclusionsWe observed primarily null associations between maternal periconceptional alcohol consumption and craniosynostosis. However, our findings do not diminish the prevailing clinical guidance in the United States that pregnant people should abstain from alcohol consumption.
Challenges of treating mantle cell lymphoma in older adults
Muñoz, Javier , Tsang, Mazie , Wang, Yucai , Phillips, Tycel , Wang, Yucai , Phillips, Tycel , Munoz, Javier L , Tsang, Mazie

Mayo Clinic

Leukemia & Lymphoma | December 11, 2024 | Volume: 66 | Issue: 3 | Pages: 433-450

10.1080/10428194.2024.2431563 | PMID 39661808 Get It

The Best Gift to Yourself: Being Okay With Being Yourself—AJR Podcast Series on Wellness, Episode 9
Wang, Sherry S.

Mayo Clinic

American Journal of Roentgenology | December 11, 2024 | Volume: 224 | Issue: 1 | Pages: No page available

10.2214/ajr.24.32472 | PMID 39660824 Get It